Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against travellers diarrhoea
8/8/2000 4:41 AM EST
Active Biotech and SmithKline Beecham agree to close collaboration regarding
vaccines against traveller's diarrhoea
Active Biotech has taken back the worldwide rights for the ETEC vaccine
project. The ongoing phase III clinical trials in Mexico and Guatemala are
continuing according to plan. Alternative partnering strategies are under
evaluation as well as the future clinical trials program.
Furthermore, all the international marketing rights for the SBL Cholera
Vaccine have been transferred back to Active Biotech.
As part of the agreement, SmithKline Beecham's (SB) paediatric vaccines,
currently sold by Active Biotech through SBL Vaccin under an agreement that
were to expire 2003, will be transferred to the Nordic organisation of SB from
1 January 2001.
In line with Active Biotechs´s strategy to focus on vaccines for travellers,
Active will receive a license for Sweden from SB regarding a second brand of
their product HAVRIX, a vaccine to prevent hepatitis A infections. This
product will be marketed by Active Biotech´s Swedish marketing organisation
SBL Vaccin.
These changes are not estimated to have any effect on the result of Active
Biotech for the years 2000 -2001.
Lund 8 August 2000
Active Biotech (Publ)
Sven Andréasson
President & CEO
Active Biotech AB is a Swedish biotechnology company focused on the research
and
development of pharmaceuticals and vaccines, the core competence being
knowledge of the
human immune system. Active Biotech has a high quality project portfolio and
considerable
financial resources. Important products and projects include Dukoral,
SBLCholera Vaccine, a vaccine
against traveller's diarrhoea (ETEC), innovative drugs against MS (SAIK) and
cancer (TTS). The
turnover of Active Biotech was SEK 267 million in 1999.
Active Biotech AB
Box 724, S-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46 19 20 50
E-mail
www.activebiotech.com www.activebiotech.com